Rowan Chapman

Bio

A Partner at Mohr Davidow, Ms Rowan was the first dedicated member of the life science investment team. She joined Mohr Davidow in 2001 and has been central to developing the life science thesis that led directly to many of the firm's life science investments. Her particular interest lies in the translation of complex data and technology to innovative products that impact drug and biofuel discovery, personalized medicine and healthcare decision making Leveraging her 19 years of business and technical experience as well as industry relationships she works closely with entrepreneurs to help develop successful businesses. She partners with entrepreneurs in a "hands on" role to help get companies started and financed Prior to joining Mohr Davidow, Ms Rowan was an early employee at Rosetta Inpharmatics where she held the position of Director of Business Development. Before the company was acquired by Merck for $620M she established many collaborative partnerships with organizations in the pharmaceutical, agricultural and biotech fields as well as among various research institutions. Previously, Ms Rowan held the position of marketing manager at Incyte Genomics She served postdoctoral fellowships at the University of California, San Francisco, as well as at the MRC-Laboratory of Molecular Biology at Cambridge. She has authored more than a dozen scientific articles and patents Ms Rowan is a board member of Sequenta and VitaPath Genetics, as well as a board observer at Artemis Health, HealthTap, Pacific Biosciences, Adamas Pharmaceuticals, CardioDx and Tethys Bioscience Ms Rowan holds a PhD in cellular and molecular biology from the MRC Laboratory of Molecular Biology in Cambridge University, UK where she also earned a bachelor's degree with first class honors in Biochemistry